(90 days)
The Respironics Q Series Auto with AFLEX CPAP System delivers positive airway pressure therapy for the treatment of Obstructive Sleep Apnea in spontaneously breathing patients weighing over 30kg (66 lbs). It is for use in the home or hospital/institutional environment.
The Respironics REMstar Q Series Auto with AFLEX CPAP System is a microprocessor controlled blower based positive pressure system with integrated heated humidifier. The REMstar Q Series Auto with AFLEX CPAP System includes the auto mode and the flex therapy feature cleared in K063830 which provides the patient with additional comfort by easing the transition from the end of inspiration to the beginning of exhalation. In addition, the device includes the AFLEX therapy feature which provides added comfort for the user (also cleared in K063830). Like its predicate, the REMstar Q Series Auto with AFLEX CPAP System is intended for use with a patient circuit that is used to connect the device to the patient interface device (mask). A typical patient circuit consists of a six-foot disposable or reusable smooth lumen 19mm tubing, an exhalation device, and a patient interface device.
This submission describes a 510(k) premarket notification for a modified CPAP system, not a study evaluating a novel device against acceptance criteria. Therefore, most of the requested information regarding acceptance criteria and performance studies cannot be extracted directly from the provided text.
Based on the provided text, the submission focuses on demonstrating substantial equivalence to a predicate device due to a "modified design." The core statement regarding performance is:
"Design verification tests were performed on the Respironics REMstar Q-Series Auto with AFLEX CPAP System as a result of the risk analysis and product requirements. All tests were verified to meet the required acceptance criteria."
However, the specific acceptance criteria, the detailed results, and the study design that "proves" the device meets these criteria are not provided in the given document. The document only states that such tests were performed and met the criteria.
Therefore, I cannot populate the table or provide detailed answers to questions 2 through 9 for a specific performance study.
Here's an attempt to address your request based on the limited information available and acknowledging what is not present:
Section 1: A table of acceptance criteria and the reported device performance
| Acceptance Criteria | Reported Device Performance |
|---|---|
| Specific acceptance criteria are not detailed in this document. It's broadly stated that tests were performed based on risk analysis and product requirements. | "All tests were verified to meet the required acceptance criteria." |
Section 2: Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Sample size for the test set: Not specified in the document.
- Data provenance: Not specified in the document. The tests performed are "design verification tests," which are typically laboratory-based and prospective, but no details are provided.
Section 3: Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
- Number of experts: Not applicable/not specified. Design verification tests for a CPAP system would typically involve engineering and possibly clinical experts for test protocol development and data interpretation, but the document does not detail this. The "ground truth" for these tests would likely be established by engineering specifications and industry standards rather than expert consensus on patient data.
Section 4: Adjudication method (e.g. 2+1, 3+1, none) for the test set
- Adjudication method: Not applicable/not specified. The document describes engineering design verification, not a clinical study requiring adjudication of expert opinions.
Section 5: If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- MRMC study: No, an MRMC comparative effectiveness study was not done. This is a medical device, specifically a CPAP system, not an AI diagnostic tool.
Section 6: If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- Standalone performance study: No, this is not an AI algorithm. The device's performance is inherent to its mechanical and software functions. The document refers to "design verification tests" for the device as a whole.
Section 7: The type of ground truth used (expert consensus, pathology, outcomes data, etc)
- Type of ground truth: The "ground truth" for the design verification tests would be established by
- Engineering specifications and performance requirements derived from risk analysis.
- Applicable standards (e.g., electrical safety, biocompatibility, performance standards for CPAP devices).
These are not equivalent to expert consensus on clinical cases or pathology.
Section 8: The sample size for the training set
- Sample size for the training set: Not applicable. This document does not describe the development of an AI model with a training set.
Section 9: How the ground truth for the training set was established
- Ground truth for the training set: Not applicable. As this is not an AI model, there is no training set or associated ground truth.
{0}------------------------------------------------
1091319
TAB 3
AUG 03 2009
510(K) SUMMARY OF SAFETY & EFFECTIVENESS
| Official Contact | Zita A. YurkoManager, Regulatory AffairsRespironics, Inc.1001 Murry Ridge LaneMurrysville, PA 15668724-387-4120724-387-4206 (fax)Email: Zita. Yurko@Respironics.com |
|---|---|
| Classification Reference | 21 CFR 868.5905 |
| Product Code | BZD - ventilator, non-continuous (respirator) |
| Common/Usual Name | CPAP System |
| Proprietary Name | Respironics REMstar Q Series Auto with AFLEX CPAP System |
| Predicate Device(s) | Respironics REMstar M Series Auto with AFLEX CPAP System(K063830) |
| Reason for submission | Modified design. |
{1}------------------------------------------------
Substantial Equivalence
The modified device has the following similarities to the previously cleared predicate device:
- O Same intended use.
- D Same operating principle.
- O Same technology.
- D Same manufacturing process.
Design verification tests were performed on the Respironics REMstar Q-Series Auto with AFLEX CPAP System as a result of the risk analysis and product requirements. All tests were verified to meet the required acceptance criteria. Respironics has determined that the modifications have no impact on the safety and effectiveness of the device. In summary, the device described in this submission is substantially equivalent to the predicate device.
The modified device complies with the applicable standards referenced in the Guidance for FDA Reviewers and Industry "Guidance for the Content of Pre-market Submissions for Software Contained in Medical Devices," May 2006.
Intended Use
The Respironics Q Series Auto with AFLEX CPAP System delivers positive airway pressure therapy for the treatment of Obstructive Sleep Apnea in spontaneously breathing patients weighing over 30kg (66 lbs). It is for use in the home or hospital/institutional environment.
Device Description
The Respironics REMstar Q Series Auto with AFLEX CPAP System is a microprocessor controlled blower based positive pressure system with integrated heated humidifier. The REMstar Q Series Auto with AFLEX CPAP System includes the auto mode and the flex therapy feature cleared in K063830 which provides the patient with additional comfort by easing the transition from the end of inspiration to the beginning of exhalation. In addition, the device includes the AFLEX therapy feature which provides added comfort for the user (also cleared in K063830). Like its predicate, the REMstar Q Series Auto with AFLEX CPAP System is intended for use with a patient circuit that is used to connect the device to the patient interface device (mask). A typical patient circuit consists of a six-foot disposable or reusable smooth lumen 19mm tubing, an exhalation device, and a patient interface device.
{2}------------------------------------------------
Image /page/2/Picture/0 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features a stylized eagle with three stripes forming its wing, symbolizing service and protection. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle, indicating the department's name and national affiliation.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-0609 Silver Spring, MD 20993-0002
AUG 0 3 2009
Ms. Zita A. Yurko Director, Regulatory Affairs Respironics, Incorporated Sleep & Respiratory Group 1001 Murry Ridge Lane Murrysville, Pennsylvania 15668
Re: K091319
Trade/Device Name: Respironics O Series Auto with AFLEX CPAP System Regulation Number: 21 CFR 868.5905 Regulation Name: Noncontinuous Ventilator (IPPB) Regulatory Class: II Product Code: BZD Dated: May 4, 2009 Received: May 5, 2009
Dear Ms. Yurko:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{3}------------------------------------------------
Page 2- Ms. Kurko
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to
http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/cdrh/mdr/ for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
For
Susan Runner, D.D.S., M.A. Acting Director Division of Anesthesiology, General Hospital, . Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
510(k) Number (if known):
Device Name: Respironics Q Series Auto with AFLEX CPAP System
Intended UseAndications for Use
The Respironics Q Series Auto with AFLEX CPAP System delivers positive airway pressure therapy for the treatment of Obstructive Sleep Apnea in spontaneously breathing patients weighing over 30kg (66 lbs). It is for use in the home or hospital/institutional environment.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) | ||
|---|---|---|
| -- | -- | -------------------------------------------------------- |
| Prescription UseXXXXXX(Per 21 CFR 801.109) | OR | Over-The-Counter Use(Optional Format 1-2-96) |
|---|---|---|
| ------------------------------------------------ | ---- | -------------------------------------------------- |
(Division Sian-Off) Division of Anesthesiology, General Hospital Infection Control, Dental Devices
510(k) Number: K091319
§ 868.5905 Noncontinuous ventilator (IPPB).
(a)
Identification. A noncontinuous ventilator (intermittent positive pressure breathing-IPPB) is a device intended to deliver intermittently an aerosol to a patient's lungs or to assist a patient's breathing.(b)
Classification. Class II (performance standards).